The restraining of MAPK/ERK signaling activation could also be a promising therapy approach in premature WMI, as the activation of MAPK/ERK signaling arrests OPC maturation and thereby leads to defective myelination in other demyelinating diseases, as stated before (Titus et al., 2017; Suo et al., 2019). The gene discussed is MAPK1; the disease is demyelinating disease.